Sleuth maps today’s standard of care line by line, dates every readout that could change it before you launch, and redraws the market for each result, so you know where to start.
Free to try on your own asset
Each line of therapy and patient group, with its standard regimen, the result to beat, how many patients there are, and how long they stay on treatment.
Every late-stage trial that could change a standard by your launch year, with its comparator, its eligibility, and a dated readout, including your own next data.
The market redrawn for each result, and the patient groups ranked for your first pivotal trial, with what would change the order.
Say what it has shown, the edge you expect, and the decision you face, plus the markets and the year you expect to launch.
Choose how to rank each patient group, such as the result to beat, patient numbers, time to readout, and competition, and how much each one counts.
See the three steps Sleuth will run: map today’s standard of care, find what could change it, and project where your asset should start. Add a trial to watch before it runs.
The patient groups ranked for your first pivotal trial, the readouts that could change the order, and the market map as a dataset.
The HR+/HER2-negative breast cancer market of 2031, redrawn for 25 readouts. Second line stays first unless the 2028 class readouts or the drug’s Phase 1b fail.
Standard of Care Evolution: HR+/HER2-negative breast cancer
Yes. The map sizes the patients and the time on treatment in each line for your launch year, which is where a forecast starts.
From company guidance or the FDA where there is one, and from the trial registry or other sources where there isn’t. The map marks which is which.
Yes. Your next data, such as a Phase 1b, goes on the timeline with every other readout, and the ranking shows where you’d start if it fails.
The markets you choose. The example maps the U.S.
Yes. Each line and patient group gets its own standard, benchmark, and patient numbers, including the groups today’s pivotal trials left out.